drugset
drugset / Trial / NCT06293898

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898 ↗

Phase 1 Recruiting 280 enrolled SystImmune Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Timeline

Start
2024-02-09
Primary completion
2028-12-15
Completion
2029-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BL-M07D1 Unknown — Intravenous

Indications

biliary tract cancer breast cancer cervical cancer endometrial cancer esophageal cancer gastric cancer gastroesophageal cancer lung cancer ovarian cancer urothelial carcinoma